Azatadine
Optimine, Trinalin (azatadine) is a small molecule pharmaceutical. Azatadine was first approved as Optimine on 1982-01-01. It is used to treat allergic rhinitis perennial, allergic rhinitis seasonal, ear diseases, respiration disorders, and urticaria in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
allergic rhinitis seasonal | EFO_0003956 | D006255 | J30 |
ear diseases | EFO_1001455 | D004427 | H93.9 |
respiration disorders | — | D012120 | J00-J99 |
urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | AZATADINE |
INN | azatadine |
Description | Azatadine is a benzo[5,6]cyclohepta[1,2-b]pyridine having a 1-methylpiperidin-4-ylidene group at the 11-position. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is a benzocycloheptapyridine and a tertiary amine. |
Classification | Small molecule |
Drug class | tricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1 |
Identifiers
PDB | — |
CAS-ID | 3964-81-6 |
RxCUI | 18600 |
ChEMBL ID | CHEMBL946 |
ChEBI ID | 2946 |
PubChem CID | 19861 |
DrugBank | DB00719 |
UNII ID | 94Z39NID6C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 86 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
142,325 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more